2023年8月23日

Signs Agreement with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

MORRISVILLE, N.C. – 2023年8月23日 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (“Wuhan Union Hospital”). This agreement expands the Company’s clinical trial capabilities across a broader range of therapeutic areas in China.

Wuhan Union Hospital now joins the Syneos Health Catalyst Site Program, introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The Program harnesses insights from sites across the globe to drive continuous improvement and develop best practices in clinical research delivery. Together, Syneos Health and Wuhan Union Hospital aim to expedite study timelines, and enable sites, sponsors and patients to be more engaged throughout the entire clinical trial process.

“Our venture with Wuhan Union Hospital is part of Syneos Health’s global strategy to accelerate our clinical development impact in this rapidly growing and changing market,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “Wuhan Union Hospital is a first-class site in China. We believe this strategic collaboration will foster a stronger development of our clinical business in Central China and enhance benefits for the patients we serve in this region.”

Ma Ming, Director of Scientific Research Department, Wuhan Union Hospital said: “As a large site in Central China, Wuhan Union Hospital has been actively cooperating with all parties with an open attitude to promote the development of the clinical trial business. Our work with Syneos Health accelerates the development of future projects and lays the foundation for strategic cooperation in other areas. We look forward to further outstanding development from both parties.”

About Syneos Health
サイネオス・ヘルス®（Nasdaq：SYNH）は、お客様の成功を後押しすることを目的として設立された完全統合された大手バイオ医薬品ソリューション組織です。臨床、メディカルアフェアーズ、およびコマーシャル事業に関する独自のインサイトを最新の市場の実態に対応できるように変換しています。  

弊社は、110を超える国々で働く有能なプロフェッショナルのチームを結集しており、患者様や医師の行動・市場ダイナミクスを熟知しています。 

弊社は一丸となって、洞察を共有し、最新技術を活用し、高度なビジネスプラクティスを応用して、お客様の重要な治療法を患者様にお届けする期間を短縮します。 

サイネオス・ヘルスは、同僚、お客様、患者様、コミュニティ、環境に配慮する、多様で公平、かつ包括的な社風を支持しています。  

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Syneos Investor Relations Contact:  Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 [email protected]

Syneos Press/Media Contact: Gary Gatyas Executive Director, External Communications +1 908 763 3428  [email protected]